Join
Live feed
·
PRReleasevia Quantisnow
Molecular Partners AG logo

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

ByQuantisnow·Wall Street's wire, on your screen.
MOLN· Molecular Partners AG
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MOLN (Molecular Partners AG) and more on Quantisnow.